Public research summary
BRVE Stock Analysis: Braveheart Bio Inc
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Data through Aug 8, 2026
- Latest close
- $20.62
- 20-day change
- -25.99%
- Trend state
- LEAN BEAR
- Classification
- Healthcare · Biotechnology
Market context
Braveheart Bio Inc moved -25.99% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BEAR.
Latest report
No complete reported period is cached yet. BullRecon keeps unavailable fundamentals explicit instead of estimating missing company results.
Six-dimension read
Company scores cover value, growth, quality, profitability, health and future financial trajectory. Scores with unavailable data are omitted.